文献速递外周血管介入泌尿生殖MRDSA

使用乙烯-乙烯醇共聚物(Onyx®)和Aetoxysclerol栓塞治疗盆腔静脉疾病:安全性和长期疗效的前瞻性评估

Embolization in pelvic venous disorders using ethylene vinyl alcohol copolymer (Onyx®) and Aetoxysclerol: a prospective evaluation of safety and long-term efficacy.
PubMed 文献 · Eur Radiol · 2022-02-08

这项前瞻性研究纳入73例连续女性盆腔静脉疾病患者,采用Onyx®和Aetoxysclerol进行栓塞治疗,中位随访28个月,临床有效率为95.9%(70/73),末次随访中位VAS损害评分从初始39/100显著降至3/100(p<0.0001),仅发生4例轻微并发症,所有患者MRI DIXON序列均可见Onyx®。

要点

  • 栓塞治疗盆腔静脉疾病临床有效率达95.9%(70/73),中位VAS损害评分从39/100降至3/100。
  • MRI DIXON序列可显示Onyx®,便于影像随访。
  • 仅发生4例轻微并发症,安全性良好。

核心结论

  • 使用Onyx®和Aetoxysclerol栓塞治疗盆腔静脉疾病安全有效。

研究设计与样本

  • 前瞻性研究,经机构伦理审查委员会批准,纳入2017年7月至2019年5月间73例连续女性患者(平均年龄41±11岁,范围25-77岁),中位随访28个月(Q1-Q3:24.0-29.2,范围18.1-34.5)。

关键影像表现/征象

  • 栓塞后3个月MRI DIXON序列所有患者均可见Onyx®。

诊断标准与关键数值

  • 临床疗效定义为损害评分<40/100且总体评分下降50%。
  • 10项临床参数(盆腔疼痛、性交痛、性交后疼痛、月经痛、下肢疼痛、行走困难、美观不适、对日常工作生活的影响、心理影响及对日常生活的影响)采用0-10分视觉模拟量表(VAS)评估,总体评分满分100分。
  • 初始中位VAS损害评分为39/100(Q1-Q3:29.75-48.50,范围12-58),末次随访中位VAS损害评分为3/100(Q1-Q3:0.00-7.25,范围0-73),较初始显著降低(p<0.0001)。
  • 临床有效率为95.9%(70/73)。

临床应用与阅片要点

  • 栓塞治疗盆腔静脉疾病后,可通过MRI DIXON序列观察Onyx®的沉积情况以辅助影像随访。
  • 临床疗效评估采用包含10项临床参数的VAS损害评分,有效标准为评分<40/100且总体评分下降50%。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

OBJECTIVES: To prospectively evaluate the safety and efficacy of embolization using ethylene vinyl alcohol copolymer (Onyx®) and Aetoxysclerol for treatment of pelvic venous disorders (PeVD).

METHODS: This prospective study was approved by the institutional ethics review board. Ten clinical parameters were retained for evaluation of PeVD (pelvic pain, dyspareunia, post-coital pain, menstruation pain, lower limbs pain, difficulty walking, aesthetic discomfort, impact on daily working life, psychological impact and impact on daily life), measured on a visual analogue scale (VAS) between 0 and 10, and a global score out of 100 was noted before embolization, after 3 months during the imaging follow-up, and at the end of follow-up by phone call. The main criterion was clinical efficacy of embolization defined by an impairment score < 40/100 and a 50% decrease in overall score. Complications were recorded. Visualization of Onyx® on MRI 3 months after embolization was noted.

RESULTS: Between July 2017 and May 2019, 73 consecutive women (mean age ± SD [range]: 41 ± 11 years [25-77]) treated by embolization with Onyx® and Aetoxysclerol were included. The median follow-up was 28 months [Q1-Q3: 24.0-29.2] (range: 18.1-34.5). The median initial VAS impairment score was 39/100 [29.75-48.50] (12-58). Clinical efficacy was obtained for 70 patients (70/73, 95.9%), and the median VAS impairment score at the end of follow-up was significantly lower at 3 [0.00-7.25] (0-73) (p < 0.0001). Four minor complications occurred. Onyx® was visualized on DIXON sequence of MRI for all patients.

CONCLUSION: Embolization using Onyx® and Aetoxysclerol for PeVD is safe and effective.

KEY POINTS: • Embolization using Onyx® and Aetoxysclerol for pelvic venous disorders is safe and effective. • Imaging follow-up is facilitated by visualization of Onyx® on MRI DIXON sequences.

来源:Eur Radiol,查看原文。版权归原作者所有。

引用

  1. Jambon, Le Bras, Coussy, et al. Embolization in pelvic venous disorders using ethylene vinyl alcohol copolymer (Onyx®) and Aetoxysclerol: a prospective evaluation of safety and long-term efficacy. Eur Radiol. 2022. PMID: 35137302. doi:10.1007/s00330-022-08567-z

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。